Skip to content

Advertisement

Journal for ImmunoTherapy of Cancer

What do you think about BMC? Take part in

Guidelines and Consensus Statements

Section edited by Robert L. Ferris, MD, PhD

This section highlights current or evolving clinical practice guidelines and consensus statements, and provides guidance to enhance clinical decision making in the field of cancer immunotherapy.

  1. Content type: Position article and guidelines

    Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a d...

    Authors: I. Puzanov, A. Diab, K. Abdallah, C. O. Bingham III, C. Brogdon, R. Dadu, L. Hamad, S. Kim, M. E. Lacouture, N. R. LeBoeuf, D. Lenihan, C. Onofrei, V. Shannon, R. Sharma, A. W. Silk, D. Skondra…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:95

    Published on:

  2. Content type: Position Article and Guidelines

    The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and dest...

    Authors: Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor III, Prasanth Abraham…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:68

    Published on:

    The Erratum to this article has been published in Journal for ImmunoTherapy of Cancer 2017 5:80

  3. Content type: Position article and guidelines

    Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that...

    Authors: Michael Boyiadzis, Michael R. Bishop, Rafat Abonour, Kenneth C. Anderson, Stephen M. Ansell, David Avigan, Lisa Barbarotta, Austin John Barrett, Koen Van Besien, P. Leif Bergsagel, Ivan Borrello, Joshua Brody, Jill Brufsky, Mitchell Cairo, Ajai Chari, Adam Cohen…

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:90

    Published on:

  4. Content type: Position article and guidelines

    Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have be...

    Authors: Douglas G. McNeel, Neil H. Bander, Tomasz M. Beer, Charles G. Drake, Lawrence Fong, Stacey Harrelson, Philip W. Kantoff, Ravi A. Madan, William K. Oh, David J. Peace, Daniel P. Petrylak, Hank Porterfield, Oliver Sartor, Neal D. Shore, Susan F. Slovin, Mark N. Stein…

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:92

    Published on:

  5. Content type: Position article and guidelines

    Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complet...

    Authors: Brian I. Rini, David F. McDermott, Hans Hammers, William Bro, Ronald M. Bukowski, Bernard Faba, Jo Faba, Robert A. Figlin, Thomas Hutson, Eric Jonasch, Richard W. Joseph, Bradley C. Leibovich, Thomas Olencki, Allan J. Pantuck, David I. Quinn, Virginia Seery…

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:81

    Published on:

Advertisement